科学 · 新闻详情
AI models need more data about biology, and OpenAI is paying to create it
真正值得关注的不是MIT 科技评论这一条动作本身，而是它可能把「医学」的竞争焦点推向更大范围的连锁反应。
发生了什么：Last year, the clinical trial policy analyst Ruxandra Teslo posted an idea for super-charging medical AI systems: use data from failed biotech companies. By bidding at their bankru…
为什么重要：它提示了一个值得继续跟踪的变化方向。
观察窗口：接下来观察它是否会引发更多同类动作，以及影响范围能否扩大。
正文来源：非原文：源网页正文只有单句或图片说明，以下为已有摘要与自动整理内容
原文链接：https://www.technologyreview.com/2026/09/15/1144129/ai-models-need-more-data-about-biology-and-openai-is-paying-to-create-it/
原文链接：https://www.technologyreview.com/2026/09/15/1144129/ai-models-need-more-data-about-biology-and-openai-is-paying-to-create-it/
Last year, the clinical trial policy analyst Ruxandra Teslo posted an idea for super-charging medical AI systems: use data from failed biotech companies.
By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—information usually kept hidden as valuable trade secrets.
She called these…
机器翻译/自动整理可能存在误差，请以原文为准。
继续阅读
正在加载推荐…